Jacobo Mintzer to Psychomotor Agitation
This is a "connection" page, showing publications Jacobo Mintzer has written about Psychomotor Agitation.
Connection Strength
3.824
-
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
Score: 0.309
-
Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies. J Clin Psychiatry. 2006; 67 Suppl 10:3-5.
Score: 0.269
-
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436.
Score: 0.174
-
Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry. 1998 Nov 01; 44(9):918-21.
Score: 0.164
-
Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457.
Score: 0.160
-
Treatment of agitation in patients with dementia. Clin Geriatr Med. 1998 Feb; 14(1):147-75.
Score: 0.155
-
Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(2):98-102.
Score: 0.154
-
Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients. Psychiatr Serv. 1997 Nov; 48(11):1435-9.
Score: 0.153
-
Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry. 1996 Aug; 57(8):372-3.
Score: 0.140
-
Principal components analysis of agitation outcomes in Alzheimer's disease. J Psychiatr Res. 2016 08; 79:4-7.
Score: 0.137
-
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.
Score: 0.135
-
Cross-cultural perspectives: agitation in demented patients in the United States. Int Psychogeriatr. 1996; 8 Suppl 3:487-90; discussion 491-2.
Score: 0.134
-
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21.
Score: 0.134
-
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109.
Score: 0.133
-
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54.
Score: 0.131
-
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67.
Score: 0.131
-
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64.
Score: 0.131
-
Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33.
Score: 0.129
-
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015 Jan; 27(1):7-17.
Score: 0.124
-
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426.
Score: 0.121
-
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91.
Score: 0.118
-
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
Score: 0.108
-
Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30.
Score: 0.102
-
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
Score: 0.076
-
Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb; 4(1):81-93.
Score: 0.072
-
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005 Nov; 13(11):942-9.
Score: 0.066
-
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002 Apr; 26(4):494-504.
Score: 0.052
-
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016 09; 82(3):784-92.
Score: 0.035
-
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry. 1996; 57 Suppl 7:55-63; discussion 73-5.
Score: 0.034
-
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
Score: 0.026
-
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
Score: 0.018